Reuters logo
Boehringer cancer drug effective in mid-stage trial
July 8, 2014 / 12:20 PM / 3 years ago

Boehringer cancer drug effective in mid-stage trial

July 8 (Reuters) - German drugmaker Boehringer Ingelheim said its experimental blood cancer drug met its main goal in a mid-stage trial.

Data showed the cancer was not found in 31 percent of the patients treated with the drug volasertib along with a chemotherapy agent versus 13.3 percent of patients who were administered the chemotherapy alone.

The drug was studied in 87 older patients with untreated acute myeloid leukemia, a type of blood cancer. (Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below